Brief: Kane Biotech secures IRB approval to launch Dispersinb Acne trial
13/03/2025 14:23
March 13 (Reuters) - Kane Biotech Inc KNE.V: KANE BIOTECH SECURES IRB APPROVAL TO LAUNCH INNOVATIVE DISPERSINB® ACNE TRIAL Source text: ID:nGNX1HXTwC Further company coverage: KNE.V ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kane Biotech
See all newsBrief: Kane Biotech Announces FDA 510(K) Clearance For Revyve® Antimicrobial Skin And Wound Cleanser
Brief: Kane Biotech Restarts Commercial Activities And Strengthens North American Management
Brief: Kane Biotech Completes U.S. FDA 510(K) Submission For Revyve Antimicrobial Wound Cleanser
Brief: Kane Biotech Announces Second Quarter 2025 Financial Results
Brief: Kane Biotech provides further corporate update